Capecitabine

Generic Name: Capecitabine

Brand Names: Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₅H_₂₂FN_₃O_₆

CAS Number: 154361-50-9

Unique Ingredient Identifier: 6804DJ8Z9U

Background: Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication: Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions: Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer

Associated Therapies: Chemotherapy

Clinical Trials

Holmium-166 TARE in Liver Limited Unresectable Colorectal Cancer Patients

Phase 2

Recruiting

Conditions: Colorectal Cancer Metastatic

Interventions: Procedure: 166Holmium TARE
Drug: Cetuximab
Drug: Panitumumab
Drug: 5-Fluorouracil
Drug: Bevacizumab
Drug: Capecitabine

First Posted Date: 2024-03-27

Last Posted Date: 2024-03-27

Lead Sponsor: Gruppo Oncologico del Nord-Ovest

Target Recruit Count: 46

Registration Number: NCT06332079

Locations: 🇮🇹
Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Phase 2

Not yet recruiting

Conditions: Metastatic Nasopharyngeal Carcinoma
Intermittent Systematic Chemotherapy

Interventions: Drug: Gemcitabine
Drug: Cisplatin
Drug: Paclitaxel protein-bound
Drug: Capecitabine
Drug: Tislelizumab

First Posted Date: 2024-03-26

Last Posted Date: 2024-03-26

Lead Sponsor: Fujian Cancer Hospital

Target Recruit Count: 39

Registration Number: NCT06331845

ELVN-002 with Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Phase 1

Recruiting

Conditions: HER2-positive Gastric Cancer
Colorectal Cancer
HER2 Amplification
HER2-positive Breast Cancer
HER2 Positive Solid Tumors

Interventions: Drug: ELVN-002
Drug: Trastuzumab
Drug: Oxaliplatin
Drug: 5-Fluorouracil
Drug: paclitaxel
Drug: Eribulin
Drug: Capecitabine
Drug: Leucovorin

First Posted Date: 2024-03-25

Last Posted Date: 2024-12-18

Lead Sponsor: Enliven Therapeutics

Target Recruit Count: 275

Registration Number: NCT06328738

Locations: 🇧🇪
Cliniques Universitaires Saint-Luc, Brussels, Belgium
🇧🇪
CHU de Liège, Liège, Belgium
🇧🇪
GZA Ziekenhuizen - Campus Sint-Augustinus, Wilrijk, Belgium

and more 26 locations

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Phase 3

Recruiting

Conditions: Breast Neoplasms

Interventions: Drug: Sacituzumab tirumotecan
Drug: Paclitaxel
Drug: Nab-paclitaxel
Biological: Pembrolizumab
Drug: Capecitabine
Drug: Liposomal doxorubicin

First Posted Date: 2024-03-15

Last Posted Date: 2024-12-05

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 1200

Registration Number: NCT06312176

Locations: 🇩🇰
Vejle Sygehus ( Site 1183), Vejle, Syddanmark, Denmark
🇳🇱
Isala, locatie Zwolle ( Site 1525), Zwolle, Overijssel, Netherlands
🇵🇹
Unidade Local de Saude de Santa Maria - Hospital de Santa Maria ( Site 1661), Lisbon, Lisboa, Portugal

and more 143 locations